To include your compound in the COVID-19 Resource Center, submit it here.

SLI 381: Phase III data; NDA under review

Data from a 51-patient Phase III trial of SLI 381 showed that patients receiving

Read the full 144 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE